Magnetothermoelectric properties of Bi2Se3

We present a study of entropy transport in Bi2Se3 at low temperatures and high magnetic fields. In the zero-temperature limit, the magnitude of the Seebeck coefficient quantitatively tracks the Fermi temperature of the 3D Fermi surface at \Gamma-point as the carrier concentration changes by two orders of magnitude (10$^{17}$ to 10$^{19}$cm$^{-3}$). In high magnetic fields, the Nernst response displays giant quantum oscillations indicating that this feature is not exclusive to compensated semi-metals. A comprehensive analysis of the Landau Level spectrum firmly establishes a large $g$-factor in this material and a substantial decrease of the Fermi energy with increasing magnetic field across the quantum limit. Thus, the presence of bulk carriers significantly affects the spectrum of the intensively debated surface states in Bi2Se3 and related materials.Comment: 10 pages, 9 figure

Cosmological Evolution of a Brane Universe in a Type 0 String Background

We study the cosmological evolution of a D3-brane Universe in a type 0 string background. We follow the brane-universe along the radial coordinate of the background and we calculate the energy density which is induced on the brane because of its motion in the bulk. We find that for some typical values of the parameters and for a particular range of values of the scale factor of the brane-universe, the effective energy density is dominated by a term proportional to $\frac{1}{(loga)^{4}}$ indicating a slow varying inflationary phase. For larger values of the scale factor the effective energy density takes a constant value and the brane-universe enters its usual inflationary period.Comment: 25 pages,1 figure,LaTex file,final version to appear in Phys. Rev.

Linear square-mass trajectories of radially and orbitally excited hadrons in holographic QCD

We consider a new approach towards constructing approximate holographic duals of QCD from experimental hadron properties. This framework allows us to derive a gravity dual which reproduces the empirically found linear square-mass trajectories of universal slope for radially and orbitally excited hadrons. Conformal symmetry breaking in the bulk is exclusively due to infrared deformations of the anti-de Sitter metric and governed by one free mass scale proportional to Lambda_QCD. The resulting background geometry exhibits dual signatures of confinement and provides the first examples of holographically generated linear trajectories in the baryon sector. The predictions for the light hadron spectrum include new relations between trajectory slopes and ground state masses and are in good overall agreement with experiment.Comment: 33 pages, 5 figures, updated to the extended version published in JHEP, vector meson bulk potential and metric corrected, comments and references added, phenomenology and conclusions unchange

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Fast computation of yearly averages of useful quantities for solar engineering

In solar engineering, many simulations require the computation of averages over a year of quantities such as the efficiency of solar plants. In the case of stationary quantities, i.e., that do not depend on the past history but only on the present conditions, time averages can be replaced by averages over the solar position, which are much faster to compute. Through a suitable choice of coordinates for the Sun position, namely, the hour angle and a declination-equivalent coordinate, the problem can be rewritten as a comparatively simple expression involving the sum of two double integrals; the solution can then be obtained numerically via suitable fast quadrature methods. The average over a year can be computed by transforming the dependence on irradiation, cloudiness, temperature or other instantaneous parameters into two dependences on Sun position – one for winter-spring (ascending declination) and one for summer-winter (descending declination). The proposed method is substantially faster than usual time integration over a year: the speedup factor ranges from 18 to almost 700 in the considered examples. It is especially well-suited to computations that require many yearly averages and could even be unfeasible otherwise. Examples of such applications include multi-parameter optimisations of the configuration of a power plant with the goal of maximizing the overall year production

Optimal focal length of primary mirrors in Fresnel linear collectors

In a linear Fresnel plant adopting slightly curved primary mirrors (cylindrical or parabolic), a significant gain in the collected radiation can be achieved using primary mirrors with different focal lengths, dependent on the position of the mirror with respect to the receiver. This work introduces a universal function that provides the optimal focal length of a mirror, given only the mirror’s position relative to the receiver and the latitude, for a NS-oriented collector with a flat horizontal effective target. In a solar plant with the focal lengths defined by this function, the efficiency gain with respect to a solar field adopting identical mirrors is estimated in the range 1.5–6%, with the gain increasing if mirror imperfections or tracking errors are present: this means that the regulation of the focal lengths is especially useful in containing the loss of efficiency due to defects. The given rule is tolerant to errors in the focal length regulation (up to 10%). The function can be used as a reference for future projects, or as a starting point for more refined optimizations